40887-80-7

Basic information

• Product Name: 3-bromophenylhydrazine
• Synonyms: 1-(3-Bromophenyl)hydrazine;(3-Bromophenyl)
• CAS NO: 40887-80-7
• Molecular Formula: C6H7BrN2
• Molecular Weight: 187.05
• EINECS: 255-130-2
• Product Categories: amine|alkyl bromide
• Mol File: 40887-80-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 174-176 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.666±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.91±0.10(Predicted)
• CAS DataBase Reference: 3-bromophenylhydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromophenylhydrazine(40887-80-7)
• EPA Substance Registry System: 3-bromophenylhydrazine(40887-80-7)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 40887-80-7(Hazardous Substances Data)

Upstream product

• 27246-81-7 3-bromophenylhydrazine hydrochloride 
• 7647-01-0 hydrogenchloride 
• 20893-74-7 3-bromophenyldiazonium chloride 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 1432508-14-9 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)-N-hydroxybenzamide 
• 1432509-23-3 methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate 
• 1432508-13-8 4-((5-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)-N-hydroxybenzamide 
• 1432509-22-2 methyl 4-((5-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate 
• 1154937-57-1 1-(3-bromo-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 
• 1281776-29-1 1-(3-bromo-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1438662-20-4 2,6-diisopropyl-N-[3-(5-methyl-1H-pyrazol-1-yl)benzyl]aniline 
• 1438662-18-0 2,6-diisopropyl-N-[3-(5-methyl-1H-pyrazol-1-yl)benzylidene]aniline 
• 1438662-16-8 3-(5-methyl-1H-pyrazol-1-yl)-benzaldehyde 
• 1260787-69-6 1-(3-bromophenyl)-5-methyl-1H-pyrazolee 
• 1438662-28-2 C₂₉H₄₆HfN₆ 
• 1438662-26-0 C₂₉H₄₆N₆Zr 
• 1450635-75-2 3-(3-bromophenyl)-1H-indole 
• 1415356-24-9 C₁₇H₁₂BrClN₂O₃ 

Relevant articles and documents

3-bromophenylhydrazine phosphate preparation method

The invention relates to a 3-bromophenylhydrazine phosphate preparation method. The method comprises the steps of diazotization, reduction, purification and salt formation. In the diazotization and reduction steps, a reaction liquid is kept strongly acidic with concentrated hydrochloric acid, such that smooth and complete reactions are ensured. In the reduction step, zinc powder-concentrated hydrochloric acid is adopted as a reducing agent for replacing sodium thiosulfate, sodium bisulfite, stannous chloride-hydrochloric acid and the like, such that reduction performance is good, yield is high, and reaction time is shortened. Impurities such as zinc hydroxide produced in the reaction are easy to remove, such that product impurity amount is low, and product purity is high. In the salt formation step, acetone is used for leaching, such that product purity is improved, and product appearance is ensured. The preparation method has the advantages of stable and reliable process, easy operation, and high product purity (product content is no lower than 99.2% as a result of high-performance liquid chromatography). A product yield is no lower than 42%. The method can completely satisfy market demands on 3-bromophenylhydrazine phosphate.

NOVEL COMPOUNDS FOR ORGANIC ELECTRONIC MATERIAL AND ORGANIC ELECTRONIC DEVICE USING THE SAME

The present invention relates to novel compounds for organic electronic material, and organic electronic devices and organic solar cells using the same. The compounds for organic electronic material may be included in a hole transport layer, electron transport layer or hole injection layer, or may be used as host or dopant. With good luminous efficiency and excellent life property of the material, they may be used to manufacture OLEDs having very good operation life.

Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold

HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor.